SCHEMBL17896337

SCHEMBL17896337

CC(C)c1cc(F)cc(NC(=O)C2CN(C)CCO2)c1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.54
MAP3K5 Q99683 1/20 0.42
ABL1 P00519 1/20 0.40
CD274 Q9NZQ7 1/20 0.39
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
USP30 Q70CQ3 4/20 0.37
MAPT P10636 1/20 0.36
ALDH1A1 P00352 2/20 0.36
ACKR3 P25106 1/20 0.35
KDM4E B2RXH2 2/20 0.34
HPGD P15428 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
RAB9A P51151 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17896802 0.85 MAP4K4 (0.56) MAP4K4MAP3K5ABL1CD274POLB
SCHEMBL19016256 0.83 MAP4K4 (0.55) MAP4K4MAP3K5ABL1CD274SMN1; SMN2
SCHEMBL21925237 0.82 MAP4K4 (0.54) MAP4K4MAP3K5ABL1CD274POLB
SCHEMBL17896335 0.81 POLB (0.60) MAP4K4POLBSMN1; SMN2ALDH1A1KDM4E
SCHEMBL21925238 0.80 MAP4K4 (0.56) MAP4K4MAP3K5ABL1CD274POLB
SCHEMBL11272707 0.74 USP30 (0.57) MAP4K4MAP3K5ABL1POLBSMN1; SMN2
SCHEMBL17896325 0.73 MAP4K4 (0.48) MAP4K4MAPTMEN1KMT2ARAB9A
SCHEMBL18626604 0.73 MAP4K4 (0.33) MAP4K4
SCHEMBL17896866 0.71 MAP4K4 (0.57) MAP4K4MAP3K5ABL1ALDH1A1RAB9A
SCHEMBL15587540 0.71 MAP4K4 (1.00) MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9855269-B2 Aminoquinazoline and pyridopyrimidine derivatives GENENTECH, INC. (US) 2018-01-02 US disclosed
US-20170173026-A1 AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES GENENTECH, INC. (US) 2017-06-22 US disclosed
US-9592235-B2 Aminoquinazoline and pyridopyrimidine derivatives GENENTECH, INC. (US) 2017-03-14 US disclosed
US-20160296525-A1 AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES GENENTECH, INC. (US) 2016-10-13 US disclosed
US-9382241-B2 Aminoquinazoline and pyridopyrimidine derivatives GENENTECH, INC. (US) 2016-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160296525-A1 AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES DPYD, FANCD2, RECQL MAP4K4 700/4885MAP3K5 419/4885ABL1 18/4885
US-20170173026-A1 AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES FLT4, FLT1, KDR MAP4K4 662/4885MAP3K5 475/4885ABL1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.